VivoSeq
Psychiatry

Bipolar 1 Disorder

3

Pipeline Programs↗

3

Active Trials↗

3

Companies Involved↗

Bipolar 1 Disorder is an early-stage landscape with 3 programs across 3 companies. The most active players are Rapport Therapeutics Inc., AbbVie, Validus Pharmaceuticals. 2 therapies are approved.

Intelligence

Pipeline Metrics

Competitive Density

25/100

Pipeline Velocity

15/100

Mech. Concentration

50/100

Completion Rate

50/100

Attrition Rate

20/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

R

Rapport Therapeutics Inc.

1 program

Phase 2AbbVie logo

AbbVie

1 program

ApprovedV

Validus Pharmaceuticals

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 21

RAP-219

Rapport Therapeutics Inc.

Phase 3
No programs
Approved2

Risperidone

Wim Janssens

Cariprazine

AbbVie

Analysis

Trial Status

5

clinical trials

Not yet recruiting2 · 40%
Terminated1 · 20%
Completed1 · 20%
Recruiting1 · 20%

Clinical Trials

Trial Activity

DB/Maintenance of Equetro (Carbamazepine) in Children With Acute Manic or Mixed Bipolar 1 Disorder
Terminated·VValidus Pharmaceuticals·Phase 4·NCT02623504·17 enrolled
Long-Term Safety Extension Trial of Asenapine in Bipolar 1 Disorder Participants Who Completed Protocol P05691 (P05692)
Completed·FForest Laboratories·Phase 3·NCT01395992·165 enrolled
Socio-cognitive and Biological Responses to Childhood Maltreatment in Individuals With Bipolar Disorder and Control Subjects
Not yet recruiting·MMedical University Innsbruck·N/A·NCT07101107·160 enrolled
Risperidone vs Cariprazine in Acute Mania a Head to Head Comparison of Efficacy vs Tolerability
Not yet recruiting·PPakistan Institute of Medical Sciences·Approved·NCT07665073·50 enrolled
A Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of RAP-219 for the Acute Treatment of Manic Episodes, With or Without Mixed Features, Associated With Bipolar I Disorder
Recruiting·RRapport Therapeutics Inc.·Phase 2·NCT07046494·250 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)